All In Biotech

Drug Trial Radar · NCT05383209

Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)

A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

77

Actual

Start

Sep 28, 2022

Primary completion

Feb 12, 2024

Study completion May 6, 2024

Sponsor

Lead sponsor
EyePoint Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.

Conditions

  • Nonproliferative Diabetic Retinopathy

Interventions

  • EYP-1901Drug

    EYP-1901 will be administered to the study eye by a single injection through the pars plana using a pre-loaded applicator with a 22-gauge needle. Each EYP-1901 IVT insert has been designed to deliver vorolanib into the vitreous humor for approximately 6 to 9 months.

  • Sham IVTOther

    Sham injections will be used to maintain masking of investigational EYP-1901 therapy for study subjects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Improved >=2 Steps From Baseline in the DRSS Score at Week 36Time frame: Baseline (Day 1) and Week 36

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • EyePoint Investigative Site

    Phoenix, Arizona

  • EyePoint Investigative Site

    Huntington Beach, California

  • EyePoint Investigative Site

    Oxnard, California

  • EyePoint Investigative Site

    Palm Desert, California

  • EyePoint Investigative Site

    Pasadena, California

  • EyePoint Investigative Site

    Poway, California

  • EyePoint Investigative Site

    Sacramento, California

  • EyePoint Investigative Site

    Danbury, Connecticut

  • EyePoint Investigative Site

    Clearwater, Florida

  • EyePoint Investigative Site

    Melbourne, Florida

  • EyePoint Investigative Site

    Miami, Florida

  • EyePoint Investigative Site

    Winter Haven, Florida

  • EyePoint Investigative Site

    Lemont, Illinois

  • EyePoint Investigative Site

    Indianapolis, Indiana

  • EyePoint Investigative Site

    Lenexa, Kansas

  • EyePoint Investigative Site

    Baltimore, Maryland

  • EyePoint Investigative Site

    Hagerstown, Maryland

  • EyePoint Investigative Site

    Springfield, Massachusetts

  • EyePoint Investigative Site

    Reno, Nevada

  • EyePoint Investigative Site

    Bloomfield, New Jersey

  • EyePoint Investigative Site

    Toms River, New Jersey

  • EyePoint Investigative Site

    Great Neck, New York

  • EyePoint Investigative Site

    Erie, Pennsylvania

  • EyePoint Investigative Site

    Florence, South Carolina

  • EyePoint Investigative Site

    Ladson, South Carolina

  • EyePoint Investigative Site

    Rapid City, South Dakota

  • EyePoint Investigative Site

    Germantown, Tennessee

  • EyePoint Investigative Site

    Abilene, Texas

  • EyePoint Investigative Site

    Austin, Texas

  • EyePoint Investigative Site

    Houston, Texas

  • EyePoint Investigative Site

    McAllen, Texas

  • EyePoint Investigative Site

    Plano, Texas

  • EyePoint Investigative Site

    San Antonio, Texas

  • EyePoint Investigative Site

    The Woodlands, Texas

  • EyePoint Investigative Site

    Lynchburg, Virginia

  • EyePoint Investigative Site

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.